KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EPS (Weighted Average and Diluted) (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.04 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 88.57% year-over-year to $0.04; the TTM value through Dec 2025 reached $0.16, up 107.34%, while the annual FY2025 figure was $0.16, 107.44% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.04 in Q4 2025 per PCRX's latest filing, down from $0.12 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.52 in Q4 2023 and bottomed at -$3.11 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.0, with a median of $0.17 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 1250.0% in 2023, then tumbled 1452.17% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.12 in 2021, then crashed by 83.33% to -$0.22 in 2022, then soared by 336.36% to $0.52 in 2023, then plummeted by 32.69% to $0.35 in 2024, then crashed by 88.57% to $0.04 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.04 in Q4 2025, $0.12 in Q3 2025, and -$0.1 in Q2 2025.